Your shopping cart is currently empty

hCYP1B1-IN-2 (compound 3n) is a potent inhibitor of the human enzyme cytochrome P450 1B1 (hCYP1B1). It exhibits strong anti-hCYP1B1 activity with an IC50 of 0.040 nM and can also block AhR transcriptional activity. hCYP1B1-IN-2 effectively inhibits hCYP1B1 through a mixed inhibition mode with a Ki value of 21.71 pM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | hCYP1B1-IN-2 (compound 3n) is a potent inhibitor of the human enzyme cytochrome P450 1B1 (hCYP1B1). It exhibits strong anti-hCYP1B1 activity with an IC50 of 0.040 nM and can also block AhR transcriptional activity. hCYP1B1-IN-2 effectively inhibits hCYP1B1 through a mixed inhibition mode with a Ki value of 21.71 pM. |
| Targets&IC50 | CYP1B1:0.040 nM, CYP1A1:0.38 nM |
| In vitro | hCYP1B1-IN-2 (compound 3n) at a concentration of 5 μM significantly reverses paclitaxel (PTX) resistance in H460/PTX cells, as demonstrated by the reduction of the IC 50 value from 632.6 nM (PTX alone) to 100.8 nM (PTX plus 3n). |
| Molecular Weight | 368.18 |
| Formula | C17H10BrN3O2 |
| Cas No. | 3043683-33-3 |
| Smiles | O=C1C=2C=CC=C3C(Br)=CC=C(C(=O)N1CC=4C=NC=NC4)C32 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.